Alogliptin benzoate for management of type 2 diabetes

Medicine & Life Sciences

• alogliptin 100%
• Benzoates 85%
• Dipeptidyl-Peptidase IV Inhibitors 78%
• Type 2 Diabetes Mellitus 44%
• Incretins 25%
• Hypoglycemia 19%
• Hypoglycemic Agents 18%
• Dipeptidyl Peptidase 4 13%
• Cardiovascular Agents 12%
• Glucose 12%
• Safety 11%
• Glucagon 10%
• Insulin Secretion 9%
• Weight Gain 9%
• Insulin 6%
• Randomized Controlled Trials 6%
• Enzymes 5%
• Therapeutics 4%

Social Sciences

• chronic illness 58%
• management 28%
• drug 26%
• adverse events 26%